Margins are genuine, stock is fully valued — Rubicon delivers but leaves no margin for error
specialty pharma · margin expansion · facility ramp-up
specialty pharma · margin expansion · facility ramp-up

specialty portfolio · manufacturing footprint · R&D productivity

generics · injectables · registrations

registrations · oncology-delay · biosimilar

EBITDA expansion · ADC platform · overseas utilization

CDMO growth · capacity constraints · forex tailwind

CDMO momentum · contract wins · capacity expansion

respiratory launches · oncology ramp · cost pressures

Librela destocking · CDMO pivot · margin compression

Librela destocking · CDMO pivot · customer concentration

earnings · pharma · acquisition

JB integration · cost synergies · semaglutide supply

semaglutide recovery · abatacept approval · base business growth

semaglutide recovery · abatacept pathway · emerging markets growth

pharma capex · EU-GMP certification · regulated markets

M&A · consolidation · strategic acquisitions

earnings · growth · guidance

revenue growth · new-age brands · geographic expansion

EU-GMP reinstatement · loss-making growth · margin compression

EU-GMP remediation · NIP/OTF pipeline · regulated markets

USFDA approval · Pitolisant · CNS drugs

CDMO · Trade Generics · Plant 6

14 consecutive quarters · CDMO 29% growth · TGx stagnant

margin collapse · acquisition dependency · organic stagnation

acquisition-led growth · margin pressure · raw material inflation

earnings beat · organic growth · material costs

Revenue +21% · Guide raised · Biotech 7-pipeline

earnings review · revenue guidance · Aequitas acquisition

brand_led_growth · semi_chronic_shift · aequitas_acquisition

earnings review · sequential weakness · Raipur profitability